GlassScriptPhysician profile
Michael David Deveau
NPI 1528301132
$5,101.54
in general payments reported to CMS, 2019-2025
35 companies · $33.38 in 2025
The $33.38 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.25 · 2020: $1,294 · 2021: $1,061 · 2022: $1,909 · 2023: $527 · 2024: $243 · 2025: $33.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,797.17 | 2020-2022 | |
| Abbott Laboratories | $494.14 | 2022-2023 | Proclaim |
| Nevro Corp. | $437.75 | 2019-2024 | Senza |
| Medtronic, INC. | $360.50 | 2023-2024 | Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $327.40 | 2022-2024 | |
| Abbvie INC. | $212.04 | 2021-2025 | Qulipta |
| Biogen, INC. | $211.41 | 2021-2022 | |
| Nutech Spine, INC. | $197.72 | 2020 | |
| Spineology INC. | $107.45 | 2022 | |
| Organogenesis INC. | $100.79 | 2020 | |
| Spr Therapeutics, INC | $100.04 | 2023-2024 | Sprint Pns System |
| Allergan, INC. | $96.66 | 2021 | |
| Kyowa Kirin, INC. | $71.92 | 2021 | |
| Collegium Pharmaceutical, INC. | $70.70 | 2022-2023 | Xtampza |
| Neurelis, INC. | $55.37 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $53.10 | 2021 | |
| Scilex Pharmaceuticals INC. | $41.06 | 2022 | |
| Jazz Pharmaceuticals INC. | $33.31 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.48 | 2022 | |
| Sk Life Science, INC. | $27.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $24.85 | 2021 | |
| Lundbeck LLC | $23.56 | 2022 | |
| Bioventus LLC | $21.65 | 2024 | Durolane |
| Curonix LLC | $19.63 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vb Spine LLC | $18.90 | 2025 | Siros |
| Valinor Pharma, LLC | $18.36 | 2024 | Movantik |
| Averitas Pharma INC. | $17.85 | 2024 | Qutenza |
| Sunovion Pharmaceuticals INC. | $17.41 | 2022 | |
| Spinal Simplicity, LLC | $16.88 | 2023 | Ha Minuteman G3-R |
| Teva Pharmaceuticals USA, INC. | $16.50 | 2021 | |
| Merz Pharmaceuticals, LLC | $16.47 | 2021 | |
| Pacira Therapeutics, INC. | $15.88 | 2021 | |
| Lilly USA, LLC | $15.18 | 2021 | |
| Forte Bio-Pharma LLC | $15.13 | 2024 | Prolate, Nalocet |
| Janssen Pharmaceuticals, INC | $14.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Deveau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.